PT  - JOURNAL ARTICLE
AU  - Sidney S. Walkenstein
AU  - Cornelius M. Knebel
AU  - Joyce A. MacMullen
AU  - Joseph Seifter
TI  - THE EXCRETION AND DISTRIBUTION OF MEPROBAMATE AND ITS METABOLITES
DP  - 1958 Aug 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 254--258
VI  - 123
IP  - 4
4099  - http://jpet.aspetjournals.org/content/123/4/254.short
4100  - http://jpet.aspetjournals.org/content/123/4/254.full
SO  - J Pharmacol Exp Ther1958 Aug 01; 123
AB  - The absorption, excretion, distribution and metabolism of C14-labeled meprobamate, labeled in both carbamate groups, following oral and intraabdominal injection was studied in rats and dogs and of the nonlabeled drug after oral administration to humans. The drug was found to be readily absorbed from the gastrointestinal tract. Significant amounts of C14 began to appear in tile Urine within 30 minutes after an oral or intra-abdominal dose and by 24 hours most had been excreted. Feces contained less than 10 per cent of the dose. Blood levels of C14 reached a peak two hours after oral administration; 50 per cent of the amount present was unchanged meprobarnate. After adnlinistration of the drug to rats, lung, kidney and liver were found to have the highest levels of radioactivity. The major metabolite, accounting for approximately 60 per cent of the dose in dogs, was isolated and identified as hydroxymeprobamate (2 - hydroxyrnethyl - 2 - n -propyl - 1 ,3 - propanediol dicarbamate). When this compound or the corresponding tricarbamate was administered to dogs no nleprobamate-like activity was observed. A specific colorimetric method for determination of meprobarnate in plasma and urine based on the Brown modification of the Kober reaction was developed and is sensitive to concentrations as low as 5 microgm. per ml.